The present study demonstrates for the first time, to the best of our knowledge, that among HER2-positive BC patients the ER status may induce specific alterations in the host biochemistry able to influence the response pattern as well as the recurrence of the disease. The gene discussed is ERBB2; the disease is breast cancer.